Evommune, Inc. shared new Phase 2 trial data on EVO756 in chronic inducible urticaria (CIndU) at the 2025 EADV Congress in Paris.
Clinical responses were observed in 93% of patients after four weeks, measured by FricTest scores or Pruritus-NRS. Improvements appeared as early as week one.
- 70% of patients improved in FricTest score at week four.
- 30% achieved complete response.
- 78% reduced Pruritus-NRS at week four.
- 41% showed ≥4-point reduction.
Rapid Onset and Broad Applicability
Patients reported improvements in both itch severity and provocation scores within one week, including three complete responders.
Half of complete responders had high baseline IgE (≥100 IU/mL). This shows efficacy across both IgE-high and IgE-low groups.
Favorable Safety and Tolerability
EVO756 was generally well-tolerated.
- No serious adverse events.
- No discontinuations due to adverse events.
Results were consistent with the Phase 1 healthy volunteer study.
Mechanism of Action
EVO756 is a potent, selective oral antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2).
- Targets mast cells and peripheral sensory neurons.
- Reduces inflammation and delivers rapid relief of itch.
- Represents a differentiated therapeutic approach compared to biologics and other treatments.
Study Design
This multicenter Phase 2 trial enrolled 30 adults with symptomatic dermographism, a common subtype of CIndU.
- Patients served as their own control.
- Screening required no spontaneous resolution during a 30-day period.
- Both IgE-high and IgE-low patients were included.
Two oral regimens were tested: 300 mg once daily (QD) and 50 mg twice daily (BID) for four weeks.
Efficacy was measured by FricTest scores and Pruritus Numeric Rating Scale. Safety was evaluated at each visit.
Expert Commentary
Edward (Ted) Lain, M.D., M.B.A., dermatologist and investigator, stated:
“Responses appeared as early as one week. EVO756 was well-tolerated and could offer an oral alternative to biologics.”
J. Mark Jackson, M.D., Vice President of Clinical Development at Evommune, added:
“By targeting MRGPRX2, EVO756 modulates mast cells and sensory neurons, addressing itch and inflammation. These results may translate into CSU and atopic dermatitis.”
Next Steps
Evommune is running Phase 2b studies:
- CSU data expected in early 2026.
- AD data expected in late 2026.
A full on-demand webinar with these results is available on Evommune’s website.
About MRGPRX2
MRGPRX2 is a GPCR found on mast cells and sensory neurons. It is activated by multiple ligands during inflammation.
Targeting MRGPRX2 could benefit several chronic inflammatory diseases and reduce neurogenic inflammation.
About EVO756
EVO756 may become the first oral MRGPRX2-targeted therapy for chronic inflammatory diseases.
- Potential in CSU and atopic dermatitis.
- May also apply to neuroinflammation.
- Offers dual modulation of mast cells and neurons.
About Evommune, Inc.
Evommune is a clinical-stage biotech developing therapies for chronic inflammatory diseases.
Its mission: improve patients’ daily lives and reduce long-term effects of uncontrolled inflammation.
